CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 316 enrolled
Drug / intervention
Tradipitant +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05903924
NCT05903924Phase 3Completed
CompareCT.gov

Motion Serifos: A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness During Travel

Vanda Pharmaceuticals·interventional·Posted Jun 15, 2023·Updated Apr 4, 2025

In Brief

A Phase 3 clinical trial evaluating Tradipitant and Placebo for Motion Sickness. Completed, enrolled 316 participants across 5 sites.

Detailed Summary

A multi-center, randomized, double-blind, placebo-controlled study to investigate the efficacy of tradipitant in participants affected by motion sickness during travel

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMotion Sickness
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
202420252026
First PostedJun 15, 2023
Enrollment StartSep 9, 2023
Primary CompletionApr 6, 2024
Study CompletionApr 24, 2024
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 3.0 years ago

Interventions

Tradipitantdrug

Oral Capsule

Placebodrug

Oral Capsule